![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMEM110 |
Gene summary for TMEM110 |
![]() |
Gene information | Species | Human | Gene symbol | TMEM110 | Gene ID | 375346 |
Gene name | STIM activating enhancer | |
Gene Alias | TMEM110 | |
Cytomap | 3p21.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q86TL2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
375346 | TMEM110 | HCC1_Meng | Human | Liver | HCC | 8.46e-19 | 2.45e-02 | 0.0246 |
375346 | TMEM110 | HCC1 | Human | Liver | HCC | 1.33e-05 | 1.51e+00 | 0.5336 |
375346 | TMEM110 | HCC2 | Human | Liver | HCC | 3.10e-11 | 2.22e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM110 | SNV | Missense_Mutation | rs372273911 | c.707C>T | p.Ser236Leu | p.S236L | Q86TL2 | protein_coding | tolerated(0.5) | benign(0) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
TMEM110 | SNV | Missense_Mutation | novel | c.469C>T | p.Leu157Phe | p.L157F | Q86TL2 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM110 | SNV | Missense_Mutation | rs377105588 | c.368N>A | p.Arg123His | p.R123H | Q86TL2 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM110 | deletion | Frame_Shift_Del | novel | c.692delN | p.Gly231GlufsTer28 | p.G231Efs*28 | Q86TL2 | protein_coding | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
TMEM110 | SNV | Missense_Mutation | novel | c.402G>T | p.Trp134Cys | p.W134C | Q86TL2 | protein_coding | tolerated(0.11) | benign(0.07) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
TMEM110 | SNV | Missense_Mutation | c.609C>G | p.Phe203Leu | p.F203L | Q86TL2 | protein_coding | tolerated(0.08) | possibly_damaging(0.487) | TCGA-55-A491-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMEM110 | SNV | Missense_Mutation | c.286N>A | p.Glu96Lys | p.E96K | Q86TL2 | protein_coding | tolerated(0.19) | benign(0.001) | TCGA-75-6214-01 | Lung | lung adenocarcinoma | Female | Unknown | III/IV | Unknown | Unknown | PD | |
TMEM110 | SNV | Missense_Mutation | novel | c.238G>C | p.Gly80Arg | p.G80R | Q86TL2 | protein_coding | deleterious(0.02) | benign(0.115) | TCGA-56-8624-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR |
TMEM110 | SNV | Missense_Mutation | rs760255234 | c.466N>T | p.Ala156Ser | p.A156S | Q86TL2 | protein_coding | tolerated(0.3) | benign(0.048) | TCGA-D6-A6EN-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
TMEM110 | SNV | Missense_Mutation | c.421N>A | p.Glu141Lys | p.E141K | Q86TL2 | protein_coding | deleterious(0.01) | possibly_damaging(0.883) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |